Oxford Nanopore Technologies
- Sector: Healthcare
- Region: South East
In the right sequence
Many companies claim to produce cutting-edge technology, but few can say their products have been used in space: Oxford Nanopore Technologies can. Its DNA/RNA sequencing technology is the only sequencing technology that offers real-time analysis, in fully scalable formats from pocket to population scale. Its vision is to enable real-time analysis of any living thing by anyone, anywhere. The portable nature of its MinION device means genome sequencing no longer has to be centralised through laboratories, saving researchers money and allowing them to work quickly in remote locations.
“Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high-performance, novel DNA/RNA sequencing technology that is accessible and easy to use,” explains Dr Gordon Sanghera, CEO of Oxford Nanopore Technologies.
Since the COVID-19 pandemic began, the company has been working with public health laboratories and researchers globally. “Initially this was to support the rapid sequencing of SARS-CoV-2, the virus that causes COVID-19. This was vital as public health authorities were trying to understand the identity of the virus, whether it was changing and how it was being transmitted, all in conjunction with other epidemiological data,” says Gordon. More recently, Oxford Nanopore has developed a test called LamPORE to detect the virus that causes COVID-19. The test is being rolled out by the UK Government and beyond.
DNA/RNA sequencing is the cornerstone of impressive advances in medicine, helping to shed light on disease and create revolutionary new drugs. “Our electronics-based DNA/RNA sequencing technology is being used in more than 100 countries, for a range of biological research applications,” explains Gordon. “These include large-scale human genomics, cancer research, microbiology, plant science and environmental research.”